Vir Biotechnology, Inc. VIR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $283.04M-23.1% | $241.07M-24.4% | $179.26M-32.2% | $306.28M-3.4% | $368M+104% | ||
| $196.28M-62.1% | $228.75M-66.3% | $327.75M-55.7% | $387.65M-54.4% | $517.37M-47.5% | ||
| $8.9M-90.6% | $1.92M-97.8% | $9.2M-89.7% | $95.2M+583% | $94.4M+608% | ||
| $168.33M-3.2% | $165.96M-8.6% | $168.54M-9.6% | $174.67M-13.8% | $173.93M-29.8% | ||
| $522.99M-43.9% | $514.08M-50.7% | $545.68M-47.9% | $735.71M-39.0% | $932.21M-23.2% | ||
| $53.16M-13.8% | $55.62M-12.0% | $58.2M-10.2% | $60.8M-8.0% | $61.68M-33.3% | ||
| $49.9M+28.4% | $47.16M+28.2% | $44.49M+26.4% | $41.56M+26.1% | $38.87M+1.9% | ||
| $60.76M+3.8% | $62.1M+4.1% | $63.56M+4.6% | $64.85M+4.2% | $58.56M-16.8% | ||
| $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | ||
| $7.78M-3.7% | $7.85M-3.3% | $7.92M-58.9% | $8M-57.7% | $8.07M-64.1% | ||
| $24.04M+310% | $24.7M+105% | $15.98M+38.3% | $13.19M-0.8% | $5.86M-53.1% | ||
| $332.97M+52.6% | $314.58M+65.6% | $304.21M+12.1% | $286.1M+2.2% | $218.14M-39.4% | ||
| $5.9M-44.9% | $6.08M— | $8.7M— | $7.3M— | $10.7M— | ||
| $1.03B-21.6% | $1B-28.3% | $1.02B-32.0% | $1.19B-28.6% | $1.31B-27.1% | ||
| $34.33M+67.5% | $32.61M+36.5% | $27.89M+10.9% | $28.35M+32.1% | $20.5M-30.4% | ||
| $68.11M-34.6% | $83.01M-15.7% | $68.38M-27.8% | $82.66M+9.7% | $104.13M+44.1% | ||
| $8.94M+12.9% | $8.8M+13.5% | $8.96M-53.8% | $8.83M-54.7% | $7.93M-33.5% | ||
| $3.3M-38.9% | $3.6M— | $4M— | $5.2M— | $5.4M— | ||
| $73.56M-46.4% | $92.82M-22.4% | $75.22M-35.8% | $105M+8.9% | $137.29M+45.9% | ||
| $86.64M-1.7% | $89.05M-1.2% | $91.22M-2.3% | $93.41M-1.7% | $88.17M-19.2% | ||
| $19.42M+31.1% | $21.58M+48.0% | $13.31M-4.2% | $13.03M-5.9% | $14.81M+4.0% | ||
| $212.82M-19.4% | $237.55M-4.4% | $223.36M-13.3% | $245.06M+3.9% | $263.91M+7.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| 300M0.0% | 300M+2,142,757% | 300M0.0% | 300M0.0% | 300M0.0% | ||
| $2.14B+11.1% | $1.97B+2.8% | $1.95B+3.1% | $1.94B+3.4% | $1.93B+4.0% | ||
| -$1.32B-50.3% | -$1.2B-57.6% | -$1.15B-76.3% | -$991.71M-125% | -$880.75M-191% | ||
| -$3.48M-76.4% | -$2.06M-19.8% | -$1.91M-270% | -$2.22M+22.9% | -$1.98M+17.6% | ||
| $812.77M-22.1% | $765.28M-33.5% | $796.1M-35.8% | $947.47M-33.9% | $1.04B-32.5% | ||
| $1.03B-21.6% | $1B-28.3% | $1.02B-32.0% | $1.19B-28.6% | $1.31B-27.1% | ||
| $196.28M-62.1% | $228.75M-66.3% | $327.75M-55.7% | $387.65M-54.4% | $517.37M-47.5% | ||
| $60.76M+3.8% | $62.1M+4.1% | $63.56M+4.6% | $64.85M+4.2% | $58.56M-16.8% | ||
| $7.78M-3.7% | $7.85M-3.3% | $7.92M-58.9% | $8M-57.7% | $8.07M-64.1% | ||
| $332.97M+52.6% | $314.58M+65.6% | $304.21M+12.1% | $286.1M+2.2% | $218.14M-39.4% | ||
| $60.76M+3.8% | $62.1M+4.1% | $63.56M+4.6% | $64.85M+4.2% | $58.56M-16.8% | ||
| $24.04M+310% | $24.7M+105% | $15.98M+38.3% | $13.19M-0.8% | $5.86M-53.1% | ||
| $103.06M+2.5% | $102.78M+2.8% | $102.69M+2.7% | $102.36M+3.4% | $100.55M-23.0% | ||
| $60.76M+3.8% | $62.1M+4.1% | $63.56M+4.6% | $64.85M+4.2% | $58.56M-16.8% | ||
| $3.39M+63.8% | $3.33M+46.7% | $3.24M+21.8% | $2.99M+5.4% | $2.07M-40.8% | ||
| $33.21M+40.5% | $34.1M+41.8% | $34.18M+3.0% | $33.62M+9.9% | $23.64M-14.4% | ||
| $68.11M-34.6% | $83.01M-15.7% | $68.38M-27.8% | $82.66M+9.7% | $104.13M+44.1% | ||
| $95.58M-0.5% | $97.85M0.0% | $100.18M-11.2% | $102.23M-10.7% | $96.1M-20.6% | ||
| $17.9M-3.2% | $17.3M-3.4% | $17.5M+18.2% | $17.2M+19.4% | $18.5M+33.1% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 161.2M+16.8% | 139.5M+1.8% | 139M+1.7% | 138.9M+1.7% | 138.1M+1.6% | ||
| 10M0.0% | 10M0.0% | 10M0.0% | 10M0.0% | 10M0.0% | ||
| 0— | 0— | 0— | 0— | 0— | ||
| 0— | 0— | 0— | 0— | 0— | ||
| $16K+14.3% | $14K0.0% | $14K0.0% | $14K0.0% | $14K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| $325K-71.9% | $1.12M— | $1.15M— | $871K— | $1.16M— | ||
| $685K+1,493% | $20K— | $67K— | $53K— | $43K— | ||
| $103.06M+2.5% | $102.78M+2.8% | $102.69M+2.7% | $102.36M+3.4% | $100.55M-23.0% | ||
| $9.04M— | $28.72M— | $20.37M— | —— | —— | ||
| $3.39M+63.8% | $3.33M+46.7% | $3.24M+21.8% | $2.99M+5.4% | $2.07M-40.8% | ||
| $37.8M— | $35.3M— | $32.03M— | —— | —— | ||
| $685K+1,493% | $20K— | $67K— | $53K— | $43K— | ||
| $325K-71.9% | $1.12M— | $1.15M— | $871K— | $1.16M— | ||
| $809.27M— | $781.59M— | $810.73M— | —— | —— | ||
| $35.11M— | $98.96M— | $17.71M— | —— | —— | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $300M0.0% | $300M0.0% | $300M0.0% | $300M0.0% | $300M0.0% | ||
| $161.23M+16.8% | $139.47M+1.8% | $139.02M+1.7% | $138.89M+1.7% | $138.06M+1.6% | ||
| $161.23M+16.8% | $139.47M+1.8% | $139.02M+1.7% | $138.89M+1.7% | $138.06M+1.6% | ||
| $1.83M-83.6% | $1.83M-84.3% | $2.12M-78.2% | $11.12M+46.2% | $11.18M+47.0% | ||
| $776.58M-21.5% | $683.36M-36.6% | $791.47M-32.8% | $875M-39.0% | $989.09M-33.6% | ||
| $7.11M+106% | $5.04M+30.1% | $1.66M-59.2% | $2.98M+2.5% | $3.45M+19.7% | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $10M0.0% | $10M0.0% | $10M0.0% | $10M0.0% | $10M0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $17.9M-3.2% | $17.3M-3.4% | $17.5M+18.2% | $17.2M+19.4% | $18.5M+33.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vir Biotechnology, Inc.'s total assets?
- Vir Biotechnology, Inc. (VIR) holds $1.0B in total assets, down 21.6% year over year.
- How much debt does Vir Biotechnology, Inc. have?
- Vir Biotechnology, Inc. carries $95.6M in total debt against $812.8M of shareholders' equity, a debt-to-equity ratio of 0.12.
- How much cash does Vir Biotechnology, Inc. have?
- Vir Biotechnology, Inc. holds $283.0M in cash and equivalents.
- Can Vir Biotechnology, Inc. cover its short-term obligations?
- Its current ratio is 7.11 — current assets exceed current liabilities.
- Where does Vir Biotechnology, Inc.'s balance sheet data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
